ABSTRACT
BACKGROUND: Women constitute over 60 percent of the HIV-infected population in sub-Saharan Africa. Highly active antiretroviral therapy (HAART) has improved the life span of people living with human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS). Advances in scientific knowledge and management of the HIV-positive pregnant woman have also led to reduction in the risk of mother-to-child transmission (MTCT) of HIV. The gynaecological and reproductive health needs and care of the HIV-positive woman are poorly appreciated, suboptimal and largely neglected, with potential to negatively affect their quality of life and efforts at control of the HIV epidemic.

OBJECTIVE: To review the contemporary gynaecological and reproductive health problems and management of the HIV-positive woman.

METHODS: A review of local and international publications on gynaecology/reproductive health and HIV from indexed/online journals and relevant websites using Pubmed and Google search in the period between 1980 and March 2009.

RESULTS: The HIV-positive woman suffers increased frequency and severity of pelvic infections and cervical pre-malignant and malignant lesions. Relapses and treatment failures of these conditions are common among these patients. Infertility and contraception are also challenges to the HIV-positive woman. Gynaecological and reproductive health care is an integral part of the comprehensive health care needs of the HIV-positive woman.

CONCLUSION: In addition to antiretroviral treatment, HIV-positive women should be provided regular screening for sexually transmitted infections (STIs), cervical cytology, counselling and services for infertility and contraception. Appropriate attention to the gynaecological and reproductive health needs of the HIV-positive woman will improve her general health status and quality of life and contribute to reduction in the incidence of HIV infection. WAJM 2010; 29(3): 135–142.

Keywords: HIV, AIDS, antiretroviral therapy, pelvic infections, cervical cytology, infertility, contraception, reproductive health.

RÉSUMÉ
CONTEXTE: Les femmes constituent plus de 60 pour cent de la population infectée par le VIH en Afrique sub-saharienne. Très active thérapie antirétrovirale (HAART) a amélioré la durée de vie de personnes vivant avec le virus de l’immunodéficience humaine (VIH) et syndrome d’immuno-déficience acquise (SIDA). Les progrès de la connaissance scientifique et la gestion du VIH positifs femme enceinte ont également conduit à la réduction du risque de la mère - À - transmission mère-enfant (TME) du VIH. Le gynécologiques et les besoins de santé génésique et les soins aux séropositifs femmes sont mal appréciés, et largement sous-optimale négligé, avec un potentiel d’affecter négativement leur qualité de la vie et les efforts de contrôle de l’épidémie de VIH.

OBJECTIF: Passer en revue le contemporain et gynécologiques problèmes de santé génésique et de la gestion de la séropositivité femme.


RÉSULTATS: La femme séropositive souffre augmenté fréquence et la gravité des infections pelviennes et cervicales, les lésions précancéreuses et cancéreuses. Les rechutes et le traitement les échecs de ces conditions sont communs chez ces patients. L’infertilité et la contraception sont aussi des défis à la séropositivité femme. Gynécologiques et les soins de santé de la reproduction est une partie intégrante des soins de santé globale des besoins de la femme VIH-positive.

CONCLUSION: En plus du traitement antirétroviral, séropositifs les femmes devraient être fournis pour un dépistage régulier les infections sexuellement transmissibles (IST), la cytologie du col utérin, services de conseil et de la stérilité et la contraception, l’attention voulue à la gynécologie et la reproduction besoins de santé de la femme VIH-positive permettra d’améliorer sa l’état de santé général et la qualité de vie et de contribuer à réduction de l’incidence de l’infection à VIH. WAJM 2010; 29 (3): 135–142.

Mots-clés: VIH, le SIDA, la thérapie antirétrovirale, les infections pelviennes, cytologie cervicale, l’infertilité, la contraception, la santé génésique.
INTRODUCTION

The World Health Organization (WHO) and Joint United Nations Programme on HIV/AIDS (UNAIDS) estimates indicate that at end of 2007, there were about 33.2 million people living with HIV globally and over 67% were in sub-Saharan Africa. Fifty percent of adults infected globally are women, but the proportion of infected persons who are women in sub-Saharan Africa is over 60%. Children (under 15 years) account for 2.5 million of the HIV-infected population and majority (90%) were acquired through mother-to-child transmission (MTCT) route. Over 90% of the yearly 420,000 new infections in children occur in sub-Saharan Africa. In addition to biological factors women in Africa are more vulnerable to HIV infection due to poverty, social inequality and deprivation. The availability and use of HAART has significantly reduced mortality associated with HIV infection and the quality of life of infected persons have also improved. Advances in scientific knowledge on HIV and management of the HIV-positive pregnant woman have also led to reduction in the risk of MTCT from over 30% to less than 2%. This has necessitated the introduction of screening for HIV among pregnant women and the use of antiretroviral drugs, modifications in obstetrics care and infant feeding in HIV-positive women.

The HIV-positive woman encounters many gynaecological problems. Though, she suffers similar range of gynaecological conditions as the HIV-negative woman, the presence of HIV, level of immune suppression and use of antiretroviral drugs influence the severity, course and response to treatment. Available evidence however, suggests that gynaecological and reproductive health care for the HIV-positive woman is poorly appreciated, suboptimal and largely neglected, with potential to affecting their quality of life. This article highlights the contemporary gynaecological problems and reproductive health issues including pelvic infections, lower genital tract malignancy, infertility and contraception in the HIV-positive woman.

SUBJECTS, MATERIALS, AND METHODS

Several published articles in local and international journals and relevant guidelines of international professional organizations were reviewed. These included published articles in journals cited in Pubmed between 1980 and March 2009 as well as other websites obtained through Google search. These articles were obtained using the key words gynaecology and HIV; reproductive health; and HIV etc. Reference lists from relevant papers were also searched.

Pelvic Infections in HIV-positive Women

Most pelvic infections are sexually transmitted and are asymptomatic. As over 80% of HIV infections are similarly acquired through heterosexual contact, both pelvic infections and HIV tend to co-exist and interact, increasing transmission and morbidity in both conditions. There is a 2–5 fold increased risk of HIV infection in persons who have ulcerative (syphilis, chancreoid and genital herpes simplex) and non ulcerative sexually transmitted infections (STIs). This has been attributed to various biologic mechanisms which include; disruption of mucosal barrier, recruitment and stimulation of HIV susceptible inflammatory cells such as CD4 lymphocytes, Langerhans cells and macrophages, increased genital tract HIV shedding and loss of protective hydrogen peroxide producing lactobacilli which assist in maintaining the acidity of the vagina. Sexually transmitted infections have been associated with increased viral load and disease progression in HIV-positive women. HIV-induced immune suppression may alter the duration of infectiousness and course of STIs. HIV-positive women co-infected with genital herpes simplex virus are more likely to shed the virus and have frequent recurrences than are HIV-negative women.

Other pelvic infections of importance associated with HIV include vulvovaginal candidiasis, pelvic inflammatory disease (PID) and genial tuberculosis. Vulvovaginal candidiasis tends to be more common, severe and persistent in HIV-positive women. The prevalence of HIV infection among PID patients is high varying from six to 22%. The HIV-positive woman with PID usually presents with higher temperature and show greater tendency to development of adnexal mass and tubo-ovarian abscess which may require surgical intervention. Genital tuberculosis is more common in HIV-positive than HIV-negative women. It results from haematogenous spread as a secondary from other parts of the body in over 90% of cases. Its prevalence is usually underestimated as efforts are not made to diagnose it even in patients with evidence of primary pulmonary tuberculosis. The recommended drug management for pelvic infections in the HIV-positive woman is essentially same as for the HIV-negative. Treatment failure is, however, more common in HIV-positive women. Careful monitoring of response to treatment is therefore needed to determine when alternative course of management becomes necessary.

The higher prevalence and incidence of pelvic infections among HIV-positive women are a major concern as untreated infections enhance transmission of the virus. It may also lead to infertility, ectopic pregnancy or chronic pelvic pains. There is therefore the need for routine sexual health screening in this group with the aim of early detection and treatment of pelvic infections and other sexual health-related conditions. A detailed sexual history and STI screen including serological investigations for syphilis and hepatitis B and C; high vaginal swabs to exclude *Candida albicans* and *Trichomonas vaginalis*; and endocervical swabs to exclude *Neisseria gonorrhoea* and *Chlamydia trachomatis* are recommended.

Cancer of the Cervix and Cervical Intraepithelial Neoplasia (CIN) in HIV-positive Women

Cancer of the cervix is the second most common cancer in women after breast cancer worldwide. It is estimated that 470,000 new cases and 270,000 deaths occur globally every year. Over 80% of the cervical cancer cases and deaths occur in developing countries, where in many regions it represents the most common female cancer and cause
of cancer deaths. Premalignant conditions (cervical intraepithelial neoplasia-CIN) of the cervix and invasive cervical cancer behave more aggressively in HIV-positive women – with higher prevalence/incidence rates, late stage presentation, more treatment failures/recurrences, poorer prognosis and younger mean age (30–40 years as against 44–52 years in the general population) at presentation.\textsuperscript{13,14} In 1993 the Centre for Disease Control and Prevention (CDC) included invasive cervical cancer as an AIDS-defining condition.\textsuperscript{13} The factors that have been identified as contributing to the altered pathophysiology of cervical lesions in HIV/AIDS patients include infection with human papilloma virus (HPV), the degree of immune suppression, the HIV-RNA viral load and the use or/ non-use of antiretroviral drugs.

Though infection with HPV is common in young sexually active persons in the general population, most infections are cleared naturally by the body’s cell mediated immune response. The CDC estimates that the lifetime risk of a sexually active man or woman becoming infected with HPV is 50%.\textsuperscript{15} Based on their oncogenic potentials, genital HPV has been grouped into two categories of high oncogenic risk (types 16, 18, 45, 33, etc) and low oncogenic risk (types 6, 11, 42, 43, 44 etc). The role of the high risk HPV in the development of CIN and cancer of the cervix is well established.\textsuperscript{17} In about 20% of women infected with high oncogenic risk HPV, a premalignant lesion develops within 2–4 years. While majority regress, some persist and a few progress to high grade CIN. Invasive cervical cancer develops from a few of such high grade CIN in an average period of 10–15 years. The prevalence rate of HPV in HIV-positive women is much higher than that in HIV-negative women (83% vs. 62% in a study).\textsuperscript{18} HIV-positive women are more at risk of high-risk HPV and multiple HPV types compared with HIV-negative women. HPV also tends to persist longer in HIV-positive women than in HIV-negative ones, resulting in higher incidence and prevalence of CIN lesions and a more rapid progression to invasive cervical cancer.\textsuperscript{19}

The degree of immune suppression is a major factor that predicts the occurrence and severity of cervical lesions. HIV-induced immune suppression leads to impaired cell-mediated immunity, with the consequence of inadequate clearance of HPV infections, and spontaneous regression of CIN lesions occur rarely. Persistent HPV and high grade CIN are more common in HIV-positive women with CD\textsubscript{4} cell count below 200/µL compared with those with higher CD\textsubscript{4} cell count.\textsuperscript{20} In addition to its effect on immune suppression, the level of HIV infection (measured by the HIV -RNA viral load) regardless of the CD\textsubscript{4} count also influences the development of cervical lesions through its modulating effect on HPV.\textsuperscript{21} While the role of HAART on the natural history of CIN remains to be fully elucidated, the increase in risk of cervical disease with low CD\textsubscript{4} count and a high HIV-RNA viral load suggest that HAART would have a positive impact. It was shown that regression in CIN among HIV-positive patients on HAART was comparable to that observed in HIV-negative women in a recent study.\textsuperscript{22} However, the effect of HAART on the incidence and prognosis of invasive cervical cancer in HIV-positive patients is yet to be clearly elucidated.

**Cervical Screening**

Screening for cervical pre-invasive disease – CIN has been the main strategy to reduce cervical cancer. Cervical cytology has similar validity in both HIV-positive and HIV-negative women. Due to the high prevalence of cervical HPV infection and CIN in HIV-positive women, CIN should be aggressively screened for and treated. Some authorities\textsuperscript{11} recommend that women newly diagnosed of HIV infection should in addition to other general medical care, have cervical cytology at diagnosis, with a follow-up at six months and yearly thereafter. Where resources allow, initial colposcopy is also recommended. Subsequent colposcopy and management of cytologic abnormality / CIN follow standard practice as in HIV-negative women.

**Management of Abnormal Cervical Cytology and Cancer of the Cervix**

The management of CIN in the HIV-positive patient is similar to that of HIV-negative. This includes excision or ablation of the lesion, adjunctive medical therapy, hysterectomy and in some situations watchful waiting. Excision or ablation therapy including large loop excision of the transformation zone, cone biopsy, cryosurgery and laser ablation is associated with success rates of 90% in the general population.\textsuperscript{23} Excisional methods have the advantage of providing specimen for histological diagnosis and free margin determination. Recurrence rates following excision of all grades of CIN are higher in HIV-positive women especially in the presence of immune deficiency. Wright et al\textsuperscript{24} reported a recurrence rate of 56% and 10% respectively among HIV-positive and HIV-negative patients. Topical vaginal 5-fluorouracil (5-FU) applied as 2g of 5% cream biweekly for six months duration have been reported to be effective in reducing recurrence rates following excision or ablation procedure for CIN in HIV-positive women.\textsuperscript{25} Watchful waiting may be applicable to patients with CIN 1 with regular follow-up cytology for up to two years while awaiting spontaneous regression. Excisional or ablative therapy becomes necessary if there is progression of cervical abnormality.

The clinical presentation, diagnosis and treatment of cancer of the cervix is essentially the same in both HIV-positive and HIV-negative women. Depending on the cancer stage management may be surgery, radiotherapy, and/or chemotherapy. Treatment outcomes are, however, poorer in HIV-positive women (with high recurrence rates of 88% in a series).\textsuperscript{26} Close follow-up is necessary after treatment of cancer of the cervix because of the high risk of recurrence.

**HPV Testing and HPV Vaccines**

While cervical screening programme has drastically reduced the incidence of cervical cancer in developed nations, same cannot be said of developing countries with little or no organized screening programme. Although HPV testing has been proposed as means of improving cervical screening by some groups, it is currently not recommended in clinical practice. Negative HPV testing may be reassuring, but the long term management of positive testing
considerations of the welfare of the child and risk of sexual, vertical and nosocomial transmission of HIV limited the offer of fertility services to people living with HIV. However, in recent times due to the effect of HAART and scientific innovation, safe procreation and infertility care can now be offered the HIV-positive couple. Issues of cross-contamination of samples and health workers have been addressed through better laboratory and clinical practices.34 When indicated, standard investigations, conventional medical/surgical treatment modalities and assisted reproductive technology (ART) used in the management of infertility in the general population also apply in HIV-positive couples. Pre-conception reproductive counselling, STI screen and basic fertility screening including seminal fluid analysis, tests for tubal patency and hormonal assay/ovulation are recommended for all HIV-positive couples who desire procreation.34,36

Options for Conception and Fertility Management in HIV-positive Couples

The options for achieving pregnancy available to the HIV-positive couple depend on whether the male, the female, or both partners are HIV-infected (Table 1). For sero-discordant couples in which the male partner is HIV-positive, the options of safe procreation include timed unprotected intercourse (TUI), donor insemination and sperm washing combined with intrauterine insemination (IUI), in-vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI). Sero-discordant couples in which the female partner is HIV-positive, the options are timed unprotected intercourse and self-insemination of partner’s semen. For sero-concordant couples (both partners being HIV-positive) the options include timed unprotected intercourse and sperm washing combined with IUI, IVF or ICSI. In all scenarios of HIV infection in the family child adoption may be considered.

Timed Unprotected Intercourse

Timed unprotected intercourse (TUI) involves the practice of engaging in unprotected sexual intercourse only during the fertile period of the woman’s menstrual cycle. Its use when the infected partner is on HAART and viral load is undetectable or less than 1000 copies/ml has been recommended as an option for couples with no access to other safer methods of achieving pregnancy.37 A prospective cohort study of 453 HIV sero-discordant couples reported a dose effect for infected patients with no transmission in cases where the infected partner had plasma viral loads of less than 1000 copies/ml.38 Barreiro et al39 in their study found no sero-conversion in 62 discordant couples who became pregnant when the viral load was undetectable in the infected partner. However, under certain conditions viral shedding in semen persists even in men with fully suppressed plasma viral load because of different compartmentalization of HIV in plasma and semen.40 Unprotected intercourse in the setting where one or both partners are HIV-infected is therefore potentially risky even in patients on HAART. In many

Table 1: Conception Options in HIV-positive Couples

<table>
<thead>
<tr>
<th>Option</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Timed Unprotected Intercourse</td>
<td>Use Fertile Period</td>
</tr>
<tr>
<td></td>
<td>Infected partner on HAART VIRAL-load</td>
</tr>
<tr>
<td></td>
<td>&lt;1000 copies/ml</td>
</tr>
<tr>
<td>Sperm Washing</td>
<td>Male-HIV-positive</td>
</tr>
<tr>
<td>Insemination with Donor Sperm</td>
<td>Male partner positive, female partner negative</td>
</tr>
<tr>
<td></td>
<td>Bars genetic parenting in male.</td>
</tr>
<tr>
<td>Self insemination with partner’s semen</td>
<td>Time insemination at ovulation</td>
</tr>
<tr>
<td>Adoption</td>
<td>Risk-free. Not popular.</td>
</tr>
</tbody>
</table>
developing countries TUI may however, be the only accessible option to many HIV-positive couples.

**Sperm Washing**

Sperm wash is applicable when the male is HIV-infected. The method of sperm wash was pioneered by Semprini et al. The technique is based on the fact that HIV is present free in seminal fluid and as cell-associated virus in leucocytes and non-spermatozoa cells but is not capable of attaching to, or infecting spermatozoa. It involves the process of sperm migration on density gradient centrifugation, repeated washing of the migrated pellet followed by swim up procedure. Polymerase chain (PCR) test for HIV is performed on aliquot of the final sample as part of quality control to confirm that the final semen product is free of HIV particles. A recent multicentre study from the Centre for Reproductive Assistance Techniques for HIV in Europe (CREATHe) showed that sperm washing procedure is safe and effective in preventing sexual transmission of HIV to uninfected partners. In this report, there were no sero-conversion in the partners who had 2840 IUI, 107 IVF, 397 ICSI and 49 frozen embryo transfers cycles, followed up for over six months after assisted reproduction attempt. The safety of washed sperm has also been attested to by other workers. It is recommended that washed sperm be used primarily for IUI in a normal (unstimulated) cycle at the time of ovulation. However, in couples with additional fertility factors, sperm washing may be combined with ovulation induction, IVF or ICSI. Some authorities prefer sperm washing combined primarily with ICSI as the treatment of choice even in the absence of any fertility factor.

**Insemination with Donor Sperm**

This is applicable when the male partner is HIV-positive but the female is negative. It involves the use of sperm from an HIV-negative donor for artificial insemination. It however, removes the chance of genetic parenting in the male.

**Self Insemination with Partner’s Semen**

Timed self insemination of partner’s semen by an IV infected woman at the time of her ovulation has been used as a risk free means of achieving pregnancy in sero-discordant settings when the male partner is HIV-negative.

**Adoption**

Adoption may serve as means of fulfilling the desire for a child in a well adjusted relationship. It is a risk-free measure and may be useful in the context where one or both partners are HIV infected. The child is, however, not a biological product of either partner. The health situation of the couple could be an obstacle in the adoption process. This is not yet a popular option in the African society.

**Contraception and HIV**

Contraception is generally required to delay, space and limit child birth. In recent times contraception has been identified as a potential tool in the reduction of the incidence of HIV infection. The WHO and United Nations agencies in 2002 recommended a four-pronged strategy to address the issue of paediatric HIV/AIDS. The strategies include – (i) primary prevention of HIV infection especially in young persons; (ii) prevention of unintended pregnancy in HIV-positive women; (iii) prevention of HIV transmission from an HIV-positive mother to her child, and (iv) provision of treatment, care and support for the HIV-positive woman, her partner and children. The availability and use of contraception is important in addressing the first and second strategies. However, in sub-Saharan Africa where the prevalence and burden of HIV/AIDS are high, contraceptive prevalence rate (CPR) is

### Table 2: Eligibility Criteria for the Use of Contraceptive Methods by HIV/AIDS Patients

<table>
<thead>
<tr>
<th>Method</th>
<th>HIV No R</th>
<th>AIDS No R</th>
<th>NRTIs</th>
<th>HIV/AIDS NNRT(NVP)</th>
<th>PI(RTV)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male &amp; Female Condom</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Diaphragm</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Cervical cap</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Spermicides</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Combined oral contraceptives</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Progestin-only pills</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Combined hormonal patch</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Injectable (DMPA)</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Injectable (NET-EN)</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Progestogen Implats</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Cu-IUD (Initiation)</td>
<td>2</td>
<td>3</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Cu-IUD (Continuation)</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>LNG-IUS (Initiation)</td>
<td>2</td>
<td>3</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>LNG-IUS (Continuation)</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Male &amp; Female Sterilization</td>
<td>A</td>
<td>S</td>
<td>A</td>
<td>A</td>
<td>A</td>
</tr>
</tbody>
</table>

**Abbreviations:** NRTIs = Nucleoside reverse transcriptase inhibitors; NNRTIs = Non-nucleoside reverse transcriptase inhibitors; NVP = Nevirapine ; PI = Protease inhibitors; RTV = Retonavir ; DMPA = Depot-medroxyprogesterone acetate; NET-EN= Norethisterone enanthate; Cu-IUD = Copper bearing intrauterine device; LNG-IUS = Levonogestrel intrauterine system; R = Treatment

**Note:** Category 1 = No restriction for use of method; Category 2 = Method could be used as advantage generally outweighs the theoretical or proven risk; Category 3 = Use of method not usually recommended unless other more appropriate methods are not available or not acceptable, as the theoretical or proven risk outweighs the advantage of use. Category 4 = Method should not be used as it is associated with an unacceptable health risk; Category A (accept) = There is no reason to delay sterilization; Category C (caution) = Performed in routine setting, but with extra preparation and precautions; Category D (delay) = Procedure is delayed until condition is properly evaluated and/or corrected. Category S (special) = Procedure should be undertaken by an experienced surgeon and staff with proper equipment for anesthesia and back up medical support.

Adapted from WHO.
also low. A recent United Nations report showed that in 2007 the CPR for sub-Saharan Africa countries was 21.5% compared with the global average of 63%. The low CPR in Africa may be attributed to factors such as high level of illiteracy, religious belief, politics, cultural value and desire for large family, preference for a particular gender and non/poor access to family planning services. The provision of appropriate contraceptive information, counseling and service to the general population including people who are HIV-positive will play a significant role in reducing the burden of HIV/AIDS in sub-Saharan Africa.

**Contraceptive Methods and Use in HIV-positive Patients**

The WHO currently assigns categories (Category 1–4 for non-permanent methods and category A, C, D and S for surgical methods) to the various contraceptive methods based on safety profile. Table 2 shows the categories of the various contraceptive methods in relation to HIV/AIDS and use of antiretroviral drugs. Dual contraception is encouraged in the context of HIV infection. This entails the simultaneous use of condom to reduce the risk of STIs/viral infection and a more effective contraception such as hormonal, intrauterine device or surgical method.

**Barrier Methods**

The barrier methods include the male and female condoms, diaphragm, cervical cap and spermicides. Apart from abstinence, condom is the only recommended method for reduction of sexual transmission of HIV. In the HIV sero-discordant couples condom use may be necessary not only to prevent pregnancy and STIs but also to prevent HIV drug resistant superinfection. In HIV-sero-discordant relationships, consistent condom use provides about 80%–95% protection from HIV transmission. Condom accidents/failures are reported in 1–2% of users. Emergency contraception and antiretroviral drugs for post-exposure prophylaxis following sexual exposure (PEPSE) may become necessary in sero-discordant relationship in condom accidents. The main drawback with male condom is that it requires male participation which may be difficult to negotiate especially in power imbalanced relationship. In such situation the female condom presents an advantage as its use is under the control of the female. The diaphragm and cervical cap covers mainly the cervix leaving most of the vaginal epithelium exposed to semen. The use of diaphragm and cervical cap with nonoxynol-9 can cause vaginal mucosa irritation and ulceration, making them unsafe and therefore not recommended in the context of HIV/AIDS.

**Hormonal Contraception**

Hormonal contraceptive methods include – combined oral contraceptive pill, progestogen-only pill, injectable progestogens and progestogen-only sub-dermal implants. The effect of hormonal contraception on HIV progression is not fully known. Available evidence suggests no association between hormonal contraceptive use and changes in HIV RNA viral load and CD4 cell counts in HIV-positive women. There are controversies as to the effect of hormonal contraceptives on HIV transmission. The available reports are inconsistent regarding whether there is increased risk in transmission. While some reports linked increased risk of HIV transmission with the use of hormonal contraception, other studies, could not demonstrate such association.

Liver enzyme-inducing drugs including antiretroviral medications and antituberculous drug (rifampicin) that are commonly used in the management of HIV-positive patients may interact with the steroids in hormonal methods with the potential of affecting the efficacy and safety of either of the drugs. The hormonal contraceptive dose in women on some antiretroviral drugs may need to be increased or alternative contraception provided. There is no restriction on the use of any of the hormonal methods for women who are HIV-positive and are antiretroviral naive.

**Combined Oral Contraceptive Pill (COC) and Progestogen-only Pill (POP)**

In current practice the low-dose COC containing 20–35µg ethinylestradiol is generally preferred to the older COC which contains 50µg ethinylestradiol or more. In order to ensure the desired efficacy, COC with higher steroid contents are recommended in HIV-positive women who are using liver-enzyme-inducing drugs. The POP is an alternative in women who cannot use oestrogen containing pills. However, the occurrence of menstrual irregularity with its use is a major disadvantage in HIV-positive patients.

**Injectable Progestogens and Progestogen-only sub-Dermal Implants**

Depo-medroxyprogesterone acetate (DMPA) is not affected by liver enzyme-inducing drugs and hence may be used in patients on various combination of HAART without the loss of its effectiveness. It can be given at the same interval as in uninfected women. The amenorrhoea that may result in up to 35% of clients is beneficial in reducing the problem of anaemia and HIV spread.

The two main progestin hormonal implants etonogestrel (Implanon®) and levonorgestrel (Jadelle®) have non-contraceptive advantage of inducing amenorrhoea with implications, of HIV transmission through reduction in viral shedding. As with most of the hormonal contraception, some antiretroviral drugs interact with the steroids with potential to reduce their efficacy.

**Intra-Uterine Devices and Surgical Sterilisation**

Under current WHO guidelines, most HIV infected women can initiate and use IUDs and users who become infected with HIV may continue using the device. However, IUD insertions are not recommended in AIDS patients who have not commenced or not responding to antiretroviral treatment as their reduced immune state makes them more vulnerable to pelvic inflammatory disease. The main disadvantage with the use of copper-bearing intrauterine device (Cu-IUD) compared with the levonorgestrel intrauterine system (LNG-IUS) is an increase in the duration of menstrual bleeding with implications for HIV transmission and anaemia. The potential effect on liver enzymes of levonorgestrel is a factor to be considered in LNG-IUS.
Surgical Methods – Sterilization

Vasectomy and bilateral tubal ligation undertaken in males and females respectively are permanent methods of contraception for couples who have completed their family. The procedures do not affect HIV transmission.

Conclusion

Many gynaecological conditions affect HIV-positive women in greater frequency and severity. Such women are also faced with challenges in safe procreation and contraception. The quality of life of the HIV-positive woman can be enhanced through regular screening and appropriate management of STIs and premalignant lesions of the lower genital tract. Preconception, infertility and family planning counseling / services should be integral parts of care provided to the HIV-positive woman.

ACKNOWLEDGEMENTS

The author would like to express gratitude to Prof S. A. Sagay of the Department of Obstetrics and Gynaecology, Jos University Teaching Hospital, Jos Nigeria for his critical reading and comments on the article.

REFERENCES